Home Cart Sign in  
Chemical Structure| 1891087-61-8 Chemical Structure| 1891087-61-8

Structure of BAY-1816032
CAS No.: 1891087-61-8

Chemical Structure| 1891087-61-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BAY-1816032 is a potent BUB1 (budding uninhibited by benzimidazoles 1) kinase inhibitor with IC50 of 7 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BAY-1816032

CAS No. :1891087-61-8
Formula : C27H24F2N6O4
M.W : 534.51
SMILES Code : FC1=C(C(F)=CC(OCCO)=C1)CN2C3=CC=CC=C3C(C4=NC=C(OC)C(NC5=CC=NC=C5OC)=N4)=N2
MDL No. :MFCD31657337

Safety of BAY-1816032

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MCF10A cells 1 nM to 10 μM 72 h To evaluate the effect of BAY-1816032 on normal mammary epithelial cell proliferation, IC50 was 18 μM. PMC11167950
T-47D cells 1 nM to 10 μM 72 h To evaluate the effect of BAY-1816032 on Luminal A subtype breast cancer cell proliferation, IC50 was 3.9 μM. PMC11167950
BT-549 cells 1 nM to 10 μM 72 h To evaluate the effect of BAY-1816032 on TNBC cell proliferation, IC50 was 1.59 μM. PMC11167950
MDA-MB-468 cells 1 nM to 10 μM 72 h To evaluate the effect of BAY-1816032 on TNBC cell proliferation, IC50 was 2.59 μM. PMC11167950
MDA-MB-231 cells 1 nM to 10 μM 72 h To evaluate the effect of BAY-1816032 on TNBC cell proliferation, IC50 was 2.10 μM. PMC11167950
SUM159 cells 1 nM to 10 μM 72 h To evaluate the effect of BAY-1816032 on TNBC cell proliferation, IC50 was 2.90 μM. PMC11167950
HCC1937 cells 250 nM 72 h To evaluate the sensitization effect of BAY1816032 to olaparib in BRCA-mutant TNBC cell line. Results showed that BAY1816032 significantly enhanced the cytotoxicity of olaparib at lower concentrations. PMC11202206
MDA-MB-231 cells 1 µM 72 h To evaluate the cytotoxic effects of BAY1816032 in combination with olaparib, cisplatin, and paclitaxel. Results showed that BAY1816032 significantly enhanced the cytotoxicity of these drugs in TNBC cell lines. PMC11202206
SUM159 cells 1 µM 72 h To evaluate the cytotoxic effects of BAY1816032 in combination with olaparib, cisplatin, and paclitaxel. Results showed that BAY1816032 significantly enhanced the cytotoxicity of these drugs in TNBC cell lines. PMC11202206
TPC-1 cells 0-50 μM 48 h Determination of IC50 value, BAY-1816032 significantly reduced cell viability PMC10948175
8505C cells 0-50 μM 48 h Determination of IC50 value, BAY-1816032 significantly reduced cell viability PMC10948175
bone marrow-derived macrophages (BMMs) 100 nM or 1 μM BAY1816032 significantly increased osteoclastogenesis in BMMs PMC11240161

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CB17/SCID mice SUM159 mammary fat pad xenograft model Oral 25 mg/kg Twice daily for four weeks To evaluate the effect of BAY-1816032 combined with radiotherapy on SUM159 xenograft tumor growth, results showed that the combination treatment significantly reduced tumor volume and prolonged animal survival. PMC11167950
Nude mice ATC xenograft model Oral 100 mg/kg Once daily for 24 days Evaluation of anti-tumor activity and safety of BAY-1816032, results showed significant reduction in tumor volume and weight PMC10948175

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.87mL

0.37mL

0.19mL

9.35mL

1.87mL

0.94mL

18.71mL

3.74mL

1.87mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories